Page 359 - Binder2
P. 359
They’ll attempt to license the tech, absorb the IP, and fold it
into the old model—without realizing that the old model is
precisely what edible biologics render obsolete.
Why This Time Might Be Different
In most cases, this strategy is sustainable. But edible
biologics are different—not just because they work, but
because they change who gets to play.
● Small nations could build their own biologic
manufacturing capacity.
● Nonprofits could launch programs without needing
a licensing partner.
● Public research institutions could distribute open-
source therapeutic crops.
● Payers could demand plant-based alternatives as
cost-saving strategies.
And when the ecosystem begins to shift from beneath them,
Big Pharma may discover that it’s not just a new product
class emerging—it’s a new paradigm forming without
them.
By the time they try to buy their way in, the market may
already belong to someone else—leaner, faster, and
aligned with a new value system.
Because edible biologics aren’t just a scientific advance.
They’re a structural reset.
And disruption, as it turns out, no longer comes from the
top.
357
